Drug Profile
CC 90003
Alternative Names: CC-90003; ERK inhibitor - CelgeneLatest Information Update: 03 Dec 2019
Price :
$50
*
At a glance
- Originator Celgene Corporation
- Class Antineoplastics
- Mechanism of Action Extracellular signal-regulated MAP kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Solid tumours
Most Recent Events
- 20 Nov 2019 Celgene Corporation has been acquired by Bristol-Myers Squibb
- 28 Jan 2018 No recent reports of development identified for phase-I development in Solid-tumours(Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (PO)
- 05 Jun 2017 Updated safety, efficacy and pharmacokinetic data from a phase Ia trial in Solid tumours (Late-stage disease, Metastatic disease, Second-line therapy or greater) presented results of the trial at the 53rd annual meeting of the American Society of Clinical Oncology (ASCO-2017)